Evidence map›Paper›PMID 42581260›Full record

ArticlePharmaceutical research2026

On-Demand Hospital Manufacturing of Baclofen Lozenges Using Pharmaceutical 3D Printing.

Daniel Grandal-Gonzalez, Carlos Bendicho-Lavilla, Eduardo Diaz-Torres, Rocio Sanin-Fontela, María L Couce, María José de Castro-López, Isabel Gonzalez-Alvarez, Marta Gonzalez-Alvarez, Alejandro Ruiz-Picazo, Marival Bermejo and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Daniel Grandal-GonzalezDepartamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, Materials Institute (iMATUS) and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain.
Carlos Bendicho-LavillaFABRX Artificial Intelligence, Enrique Vidal Abascal 7, 15702, Santiago de Compostela, Spain.
Eduardo Diaz-TorresFABRX Artificial Intelligence, Enrique Vidal Abascal 7, 15702, Santiago de Compostela, Spain.
Rocio Sanin-FontelaDepartamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, Materials Institute (iMATUS) and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain.
María L CouceServicio de Neonatología, Unidad de Diagnóstico y Tratamiento de Enfermedades Metabólicas Congénitas, Health Research Institute of Santiago de Compostela (IDIS), Hospital Clínico Universitario de Santiago de Compostela, Universidad de Santiago de Compostela, IDIS, RICORS, CIBERER, MetabERN, Santiago de Compostela, Spain.
María José de Castro-LópezServicio de Neonatología, Unidad de Diagnóstico y Tratamiento de Enfermedades Metabólicas Congénitas, Health Research Institute of Santiago de Compostela (IDIS), Hospital Clínico Universitario de Santiago de Compostela, Universidad de Santiago de Compostela, IDIS, RICORS, CIBERER, MetabERN, Santiago de Compostela, Spain.
Isabel Gonzalez-AlvarezDepartment of Pharmacokinetics and Pharmaceutical Technology, Miguel Hernandez University, 03550, San Juan de Alicante, Spain.
Marta Gonzalez-AlvarezDepartment of Pharmacokinetics and Pharmaceutical Technology, Miguel Hernandez University, 03550, San Juan de Alicante, Spain.
Alejandro Ruiz-PicazoDepartment of Pharmacokinetics and Pharmaceutical Technology, Miguel Hernandez University, 03550, San Juan de Alicante, Spain.
Marival BermejoDepartment of Pharmacokinetics and Pharmaceutical Technology, Miguel Hernandez University, 03550, San Juan de Alicante, Spain.
Pedro Garcia-SalomPharmacy Service, Dr. Balmis General University Hospital, 03010, Alicante, Spain.
Abdul W BasitFABRX Artificial Intelligence, Enrique Vidal Abascal 7, 15702, Santiago de Compostela, Spain.
Carmen Alvarez-LorenzoDepartamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, Materials Institute (iMATUS) and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain. carmen.alvarez.lorenzo@usc.es.
Alvaro GoyanesDepartamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, Materials Institute (iMATUS) and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782, Santiago de Compostela, Spain. a.goyanes@fabrx.co.uk.

Funding

Consellería de Cultura, Educación e Ordenación Universitaria, Xunta de Galicia ED431C 2024/09Fundación Mutua Madrileña AP180872022Ministerio de Ciencia, Innovación y Universidades PID2023-149544OB-C22
6 · The paper itself

Abstract

purposeDysphagia in neurological patients complicates oral drug administration. Manual preparation of lozenges/troches lacks precision and scalability. This study investigates the feasibility of implementing a pharmaceutical 3D printer in a hospital pharmacy for the automated production of personalized baclofen troches.

methodsBaclofen troches were manufactured in a hospital pharmacy setting, both manually and via pharmaceutical 3D printer. Quality was evaluated using Process Analytical Technologies (PAT). Performance was assessed through European Pharmacopoeia (EP) tests for drug content, mass uniformity, in vitro dissolution, disintegration, and a six-month stability study.

resultsPrinted troches complied with all EP acceptance criteria for drug content and mass uniformity, whereas manual formulations failed, particularly at the lowest dose. Printed troches demonstrated immediate drug release, consistent quality across batches, and remained stable for six months. 3D printing showed superior precision over traditional manual compounding.

conclusionsThis research describes the first successful implementation of an automated blister-filling workflow using a pharmaceutical 3D printer within a hospital pharmacy setting, spanning from manufacturing and dispensing to direct patient administration. The automated approach provides a significant advancement in personalized medicine, ensuring safer, more accurate, and efficient treatment options for patients with specific needs like dysphagia.

Indexed as

impaired swallowing functionpersonalized pharmaceuticalspharma-inkprocess analytical technologiessemi-solid extrusion (SSE) 3D printing

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.